Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodesix, Inc. (BDSX) SEC filings page on Stock Titan brings together the company’s official disclosures as a Nasdaq-listed diagnostic solutions company. Through its reports to the U.S. Securities and Exchange Commission, Biodesix provides detail on its diagnostic testing and development services businesses, capital structure, and material corporate events.
Investors can use this page to access current and historical filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe revenue from Lung Diagnostics and Development Services, operating metrics, and risk factors relevant to a diagnostics and health care business. These core filings typically discuss Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, as well as the company’s work with biopharmaceutical and life sciences partners.
Biodesix also files Forms 8-K to report specific material events. Recent 8-K filings document actions such as a one-for-twenty reverse stock split of the company’s common stock, the related amendment to its certificate of incorporation, elimination of a preferred stock series, and confirmation that the company regained compliance with Nasdaq’s minimum bid price requirement. Other 8-Ks furnish press releases announcing quarterly financial and operating results.
On this page, users can review insider and capital structure-related filings when available, including information about changes to equity, preferred stock designations, and other securities. These documents help clarify how corporate actions affect common stockholders and outstanding awards or warrants.
Stock Titan enhances access to Biodesix filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify discussions of revenue composition, diagnostic and development services, stock listing matters, and significant corporate changes. Real-time updates from the EDGAR system ensure that new Biodesix 10-K, 10-Q, 8-K, and related filings appear promptly, while AI-generated overviews provide a starting point for deeper review of the full regulatory text.
Biodesix Inc (BDSX) CFO Robin Harper Cowie reported routine equity award activity and a small tax-related share sale. On February 20, 2026, 1,469 restricted stock units were exercised into 1,469 shares of common stock at a price of $0.00 per share, increasing directly held common stock to 16,766 shares.
On February 23, 2026, Cowie sold 535 shares of common stock in an open‑market transaction at a weighted average price of $12.7756 per share, leaving 16,231 common shares directly owned. Footnotes state these shares were sold automatically by the issuer’s broker to cover taxes upon RSU vesting, in multiple trades ranging from $12.58 to $13.16 per share.
Each RSU represents a right to receive one share of common stock, and the RSUs vest in four equal annual installments beginning February 20, 2025, generally subject to continued service. The holdings and award numbers reflect a one‑for‑twenty reverse stock split effective September 15, 2025.
Biodesix Inc Chief Accounting Officer Chris Vazquez reported equity transactions involving restricted stock units (RSUs) and common stock. On February 20, 2026, RSUs covering 563 shares were exercised for no cash cost, converting into the same number of common shares. Following this, on February 23, 2026, 211 common shares were sold in open-market transactions at a weighted average price of $12.7756 per share to cover taxes due upon RSU vesting, with individual sale prices ranging from $12.58 to $13.16. After these transactions, Vazquez directly held 1,586 common shares and 1,689 RSUs, with the RSUs scheduled to vest in four equal annual installments starting February 20, 2025.
Biodesix Inc. President & CEO Scott Hutton reported equity transactions involving company stock and restricted stock units. On February 20, 2026, 4,844 restricted stock units were exercised into 4,844 shares of common stock at $0.00 per share, increasing his direct common share holdings to 50,257 and leaving 14,531 RSUs outstanding. On February 23, 2026, 1,490 common shares were sold in open-market transactions at a weighted average price of $12.7756 per share, in a price range from $12.58 to $13.16, with the sale made automatically by the issuer’s broker to cover taxes upon RSU vesting. Following these transactions, he directly owned 48,767 shares of Biodesix common stock.
BDSX reports a Section 144 notice for the resale of 4,844 shares of common stock to settle vested RSUs under its S-8 plan. The filing also records prior open-market dispositions by Scott Hutton of 3,559 shares on 02/10/2026 and 970 shares on 01/16/2026.
O'Kane Kieran reported multiple insider transaction types in a Form 4 filing for BDSX. The filing lists transactions totaling 3,784 shares at a weighted average price of $10.08 per share. Following the reported transactions, holdings were 9,469 shares.
Biodesix, Inc. Chief Accounting Officer Chris Vazquez reported equity award activity and a small share sale. On February 9, 2026, RSUs were converted into 263 shares of Common Stock, increasing direct holdings to 1,335 shares, and RSU positions were adjusted following a one-for-twenty reverse split.
On February 10, 2026, Vazquez executed an open‑market sale of 101 Common shares at a weighted average price of $10.0841, conducted automatically to cover taxes upon RSU vesting, leaving 1,234 Common shares held directly and 234 RSUs outstanding, which vest over time subject to continued service.
Biodesix, Inc. President & CEO Scott Hutton reported equity award activity and a related share sale. On February 9, 2026, he acquired 9,998 shares of Common Stock through the exercise of restricted stock units (RSUs), bringing his direct Common Stock holdings to 48,972 shares.
On February 10, 2026, 3,559 Common Shares were sold in an open-market transaction at a weighted average price of $10.0841 to cover taxes due upon RSU vesting, leaving him with 45,413 Common Shares held directly. RSU activity included the conversion of 610 RSUs that fully vested and 9,388 RSUs that remain outstanding, with vesting schedules tied to continued service and figures adjusted for a one-for-twenty reverse stock split effective September 15, 2025.
Biodesix Inc. CFO Robin Harper Cowie reported equity compensation activity tied to restricted stock units (RSUs). On February 9, 2026, RSUs were converted into 2,584 shares of Common Stock, and RSU balances were updated, including 2,426 unvested RSUs after adjustment for a prior reverse split.
On February 10, 2026, Cowie executed an automatic open-market sale of 941 Common shares at a weighted average price of $10.0841 to cover taxes upon RSU vesting, leaving 15,297 Common shares held directly.
Biodesix Inc. Chief Development Officer Gary Anthony Pestano reported equity transactions involving company stock. On February 9, 2026, he acquired 1,481 shares of Common Stock through the exercise/conversion of restricted stock units (RSUs), bringing his direct holdings to 9,927 shares.
On February 10, 2026, 540 shares of Common Stock were sold at a weighted average price of $10.0841 per share, automatically to cover taxes upon RSU vesting. After this tax-related sale, Pestano directly owned 9,387 shares of Biodesix Common Stock. The filing also notes RSU grants that vest over time and that the reported RSU numbers reflect a one-for-twenty reverse stock split effective September 15, 2025.
Jack W. Schuler has updated his beneficial ownership in Biodesix, Inc. through Amendment No. 10 to his Schedule 13D. He now reports beneficial ownership of 2,333,945 shares of Biodesix common stock, representing about 24% of the outstanding shares, based on 9,685,789 shares outstanding plus 20,735 shares he can acquire within 60 days.
Recent open-market activity includes purchases through the Jack W. Schuler Living Trust of 82,465 shares on January 22, 2026 at a weighted average price of $10.9569, 80,000 shares on January 23, 2026 at $11.8084, and 20,000 shares on January 26, 2026 at $11.8032 per share. His reported holdings comprise 4,156 option shares and 16,579 RSU shares exercisable or settling within 60 days, 1,563,210 shares held by the Living Trust (about 16.1% of the class), and 750,000 shares held by the 2025 GRAT (about 7.7% of the class). Schuler serves as sole trustee of both entities and transitioned to emeritus director status at the May 20, 2025 annual meeting.